The FDA has approved a combination therapy of pembrolizumab, carboplatin, and paclitaxel for advanced endometrial cancer, significantly enhancing progression-free survival rates for patients with both mismatch repair deficient and proficient statuses.

The study demonstrates that tirzepatide significantly reduces apnea–hypopnea index and body weight in patients with obstructive sleep apnea and obesity, indicating its potential role in improving both sleep and metabolic health.

Physician salaries have increased by 3% on average in 2024, with notable disparities across specialties, gender, and ethnicity impacting overall satisfaction. Orthopedics and plastic surgery remain the top earners, while diabetes and endocrinology are at the lower end.

A comprehensive study spanning over two decades has found no evidence that daily multivitamin use reduces the risk of death from any cause, including cancer and cardiovascular disease.

In a phase 3 trial, the combination of amivantamab and lazertinib resulted in a median progression-free survival of 23.7 months, surpassing the 16.6 months observed with osimertinib in patients with EGFR-mutated advanced NSCLC.

With nearly ten years of follow-up, dabrafenib plus trametinib demonstrates a sustained improvement in survival outcomes for patients with stage III BRAF V600–mutated melanoma, presenting a viable long-term strategy in melanoma management.